Novartis AG — Director's Dealing 2017

Jun 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ra Pharmaceuticals, Inc. (RARX)
CIK: 0001481512
Period of Report: 2017-06-16

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-16	Common Stock	S	53200	$21.2445	Disposed	2254677	Direct
2017-06-19	Common Stock	S	3220	$22.0182	Disposed	2251457	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $21.00 to $21.67 on June 16, 2017 and $22.00 to $22.04 on June 19, 2017. The prices reported reflect the weighted average sale prices. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.